Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)
Eric Lawitz
(1)
,
Edward J. Gane
(2)
,
Brian Pearlman
(3)
,
Edward Tam
,
Wayne Ghesquiere
,
Dominique Guyader
(4)
,
Laurent Alric
(5)
,
Jean-Pierre Bronowicki
(6)
,
Lorenzo Rossaro
(7)
,
William Sievert
(8)
,
H. Ghalib Reem
(9)
,
A. Balart Luis
(10)
,
Fredrik Sund
(11)
,
Martin Lagging
(12)
,
Frank Dutko
(13)
,
Y. Howe Anita
(13)
,
Melissa Shaughnessy
(13)
,
Peggy Hwang
(13)
,
Janice Wahl
(13)
,
Michael Robertson
(13)
,
A Haber Barbara
(13)
1
University of North Texas Health Science Center [Fort Worth]
2 University of Auckland [Auckland]
3 CDC - Centers for Disease Control and Prevention [Atlanta]
4 UR - Université de Rennes
5 PHARMA-DEV - Pharmacochimie et Biologie pour le Développement
6 UL - Université de Lorraine
7 UC Davis - University of California [Davis]
8 Monash University [Melbourne]
9 Central Texas Clinical Research
10 Tulane University
11 Uppsala University
12 GU - Göteborgs Universitet = University of Gothenburg
13 Merck & Co. Inc - Merck Sharp and Dohme
2 University of Auckland [Auckland]
3 CDC - Centers for Disease Control and Prevention [Atlanta]
4 UR - Université de Rennes
5 PHARMA-DEV - Pharmacochimie et Biologie pour le Développement
6 UL - Université de Lorraine
7 UC Davis - University of California [Davis]
8 Monash University [Melbourne]
9 Central Texas Clinical Research
10 Tulane University
11 Uppsala University
12 GU - Göteborgs Universitet = University of Gothenburg
13 Merck & Co. Inc - Merck Sharp and Dohme